Celyad, the former Cardio3 Biosciences, filed to make a $115 million debut on the Nasdaq, stretching its focus from heart treatments to the fast-growing field of cancer immunotherapy. The biotech, already listed on the Euronext exchange, is looking to make the leap to Wall Street as it repositions its pipeline, expanding beyond its cell therapies for heart failure and diving into CAR-T treatments, developing products that use a patients' own immune cells to fight blood cancers. More